ALB and esophageal cancer: The present study of camrelizumab in combination with albumin paclitaxel and carboplatin in borderline resectable or unresectable locally advanced esophageal cancer was a single‐arm, single‐center trial, in which we also demonstrated that locally advanced esophageal cancers that are not resected prior to surgery at R0 require preoperative transformative therapy, which is in line with previous studies11